The DOI matches its Crossref record; 344 of the 344 references it cites were found in a registry or an index.
Malignant Pleural Mesothelioma
Open accessAbstract
Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–344 of 344
Gene Therapy Approaches for Inherited and Acquired Lung Diseases
Curiel, D. T., Pilewski, J. M., & Albelda, S. Μ. (1996) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.14.1.8534480 · Cited by 94
SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure
Cacciotti, P., Barbone, D., Porta, C., Altomare, D. A., Testa, J. R., Mutti, L., & Gaudino, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0127 · Cited by 94
Bianchi, A. S., Gasparri, F., Galvani, A. P., Nici, L. L., Darnowski, J. W., Barbone, D., Fennell, D. A., Gaudino, G., Porta, C., & Mutti, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0536 · Cited by 94
Prospective Study of Mesothelioma Mortality in Turkish Villages With Exposure to Fibrous Zeolite
Baris, Y. I., & Grandjean, P. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj106 · Cited by 93
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
Kumar‐Singh, S., VERMEULEN, P. B., Weyler, J., Segers, K., Weyn, B., Daele, A. V., Dirix, L. Y., OOSTEROM, A. T. V., & Marck, E. V. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199706)182:2<211::aid-path834>3.0.co;2-d · Cited by 92
Thalidomide in patients with malignant pleural mesothelioma
Baas, P., Boogerd, W. J., Dalesio, O., Haringhuizen, A., Custers, F. L. J., & van Zandwijk, N. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.005 · Cited by 92
Prins, J., Williamson, K. A., Kamp, M., Hezik, E. J. V., van der Kwast, T., Hagemeijer, A., & Versnel, M. A. (1998) · International Journal of Cancer · Cited by 92
Gill, R. R., Umeoka, S., Mamata, H., Tilleman, T. R., Stanwell, P., Woodhams, R., Padera, R. F., Sugarbaker, D. J., & Hatabu, H. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.3519 · Cited by 89
Zellos, L. S., Richards, W. G., Capalbo, L., Jaklitsch, M. T., Chirieac, L. R., Johnson, B. E., Bueno, R., & Sugarbaker, D. J. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.07.055 · Cited by 88
Russell, S. J., Eccles, S. A., Flemming, C. L., Johnson, C. A., & Collins, M. K. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470213 · Cited by 87
Zidar, B. L., Green, S., Pierce, H. I., et al. (1988) · Investigational New Drugs · doi:10.1007/bf00175403 · Cited by 87
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
van den Bogaert, D. P. M., Pouw, E. M., van Wijhe, G., Vernhout, R. M., Surmont, V. F. M., Hoogsteden, H. C., & van Klaveren, R. J. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31509-4 · Cited by 87
Yan, T. D., Boyer, M. J., Tin, M. M., Wong, D., Kennedy, C. J., McLean, J. M., Bannon, P. G., & McCaughan, B. C. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.12.045 · Cited by 85
van Ruth, S., Baas, P., Haas, R. L., Rutgers, E. J. T., Verwaal, V. J., & Zoetmulder, F. A. N. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.022 · Cited by 85
Flores, R. M., Routledge, T., Seshan, V., Dycoco, J., Zakowski, M. F., Hirth, Y., & Rusch, V. W. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.02.069 · Cited by 84
Treatment of Malignant Mesothelioma
Jaklitsch, M. T., Grondin, S. C., & Sugarbaker, D. J. (2001) · World Journal of Surgery · doi:10.1007/s002680020021 · Cited by 84
Extended Surgical Staging for Potentially Resectable Malignant Pleural Mesothelioma
Rice, D. C., Erasmus, J. J., Stevens, C. W., Vaporciyan, A. A., Wu, J. S., Tsao, A. S., Walsh, G. L., Swisher, S. G., Hofstetter, W. L., Ordóǹez, N. G., et al. (2005) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2005.06.014 · Cited by 83
Self-citationMalignant pleural mesothelioma
Baas, P., Schouwink, H., & Zoetmulder, F. A. N. (1998) · Annals of Oncology · doi:10.1023/a:1008239116237 · Cited by 83
Vitamin A and cancer prevention II: Comparison of the effects of retinol and β-carotene
de Klerk, N. H., Musk, A. W., Ambrosini, G. L., Eccles, J. L., Hansen, J., Olsen, N. J., Watts, V. L., Lund, H., Pang, S., Beilby, J. P., et al. (1998) · International Journal of Cancer · Cited by 82
Effect of Interferon-α 2a Malignant Mesothelioma
CHRISTMAS, T. I., Manning, L. S., Garlepp, M. J., Musk, A. W., & Robinson, B. W. S. (1993) · Journal of Interferon Research · doi:10.1089/jir.1993.13.9 · Cited by 81
Galateau-Sallé, F., Bidet, P., Iwatsubo, Y., Gennetay, E., Renier, A., Letourneux, M., Pairon, J. ‐., Moritz, S., Brochard, P., Jaurand, M., et al. (1998) · The Journal of Pathology · Cited by 81
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
Treasure, T., Waller, D. A., Tan, C. H. C., Entwisle, J. J., O’Brien, M., O'Byrne, K. J., Thomas, G., Snee, M., Spicer, J. F., Landau, D., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ae26ae · Cited by 81
Flores, R. M., Riedel, E., Donington, J. S., Alago, W., Ihekweazu, U. N., Krug, L. M., Rosenzweig, K. E., Adusumilli, P. S., Carbone, M., & Pass, H. I. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1903e · Cited by 81
van Meerbeeck, J. P., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H. J. M., Pinson, P., Glabbeke, M. M. V., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.465 · Cited by 81
de Perrot, M. E., Uy, K. F. L., Anraku, M., Tsao, M., Darling, G. E., Waddell, T. K., Pierre, A. F., Bezjak, A., Keshavjee, S. H., & Johnston, M. R. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.06.044 · Cited by 80
PTEN expression is a strong predictor of survival in mesothelioma patients☆
Opitz, I., Soltermann, A., Abaecherli, M., Hinterberger, M., Probst-Hensch, N. M., Stahel, R. A., Moch, H., & Weder, W. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2007.09.045 · Cited by 80
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
Pg, S., Bach, F., Bork, E., & Hh, H. (1985) · PubMed · Cited by 80
Therapeutic radiation for lymphoma
Teta, M. J., Lau, E., Sceurman, B. K., & Wagner, M. E. (2007) · Cancer · doi:10.1002/cncr.22526 · Cited by 79
Ultrastructural features of diffuse malignant mesotheliomas
Oury, T. D., Hammar, S. P., & Roggli, V. L. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90006-5 · Cited by 79
Lu, C. S., Perez-Soler, R., Piperdi, B., Walsh, G. L., Swisher, S. G., Smythe, W. R., Shin, H. J. C., Ro, J. Y., Feng, L., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.802 · Cited by 79
Edwards, J. G., Stewart, D., Martin-Ucar, A. E., et al. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2005.11.044 · Cited by 78
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary
Maziak, D. E., Gagliardi, A. R., Haynes, A. E., Mackay, J. A., & Evans, W. K. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.003 · Cited by 78
Ardizzoni, A., Rosso, R., Fusco, V., Pennucci, M. C., Santi, L., Salvati, F., Cinquegrana, A., Palma, M. D., Serrano, J., Soresi, E., et al. (1991) · Cancer · Cited by 78
Musk, A. W., de Klerk, N. H., Ambrosini, G. L., Eccles, J. L., Hansen, J., Olsen, N. J., Watts, V. L., Lund, H., Pang, S., Beilby, J. P., et al. (1998) · International Journal of Cancer · Cited by 77
Balsara, B., Bell, D. W., Sonoda, G., Rienzo, A. D., du Manoir, S., Jhanwar, S. C., & Testa, J. R. (1999) · PubMed · Cited by 77
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
Vogelzang, N. J., Weissmann, L. B., Herndon, J. E., Antman, K. H., Cooper, M. R., Corson, J. M., & Green, M. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1436 · Cited by 77
Hopkins-Donaldson, S., Cathomas, R. L., Simões‐Wüst, A. P., Kurtz, S., Belyanskya, L., Stahel, R. A., & Zangemeister‐Wittke, U. (2003) · International Journal of Cancer · doi:10.1002/ijc.11209 · Cited by 76
Belyanskaya, L. L., Marti, T. M., Hopkins-Donaldson, S., Kurtz, S., Felley‐Bosco, E., & Stahel, R. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-66 · Cited by 76
Rusch, V. W. (1997) · PubMed · Cited by 76
Schneider, J., Hoffmann, H., Dienemann, H., Herth, F. J. F., Meister, M. A., & Muley, T. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318187491c · Cited by 75
Katirtzoglou, N., Gkiozos, I., Makrilia, N., Tsaroucha, E., Rapti, A., Stratakos, G., Fountzilas, G., & Syrigos, K. N. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.005 · Cited by 75
Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging of Malignant Pleural Mesothelioma
Rice, D. C., Steliga, M. A., Stewart, J., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.05.022 · Cited by 75
Janne, P. A., Wozniak, A. J., Belani, C. P., Keohan, M. L., Ross, H. J., Polikoff, J. A., Mintzer, D. M., Ye, Z., Monberg, M., & Obasaju, C. K. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30351-8 · Cited by 74
Flores, R. M. (2009) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2009.06.008 · Cited by 74
Plathow, C., Klopp, M., Thieke, C., Herth, F. J. F., Thomas, A., Schmähl, A., ZUNA, I., & Kauczor, H. (2008) · European Radiology · doi:10.1007/s00330-008-0918-9 · Cited by 74
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma
Halstead, J. C., Lim, E., Venkateswaran, R., et al. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.08.014 · Cited by 73
Greillier, L., Cavailles, A., Fraticelli, A., Scherpereel, A., Barlési, F., Tassi, G., Thomas, P. A., & Astoul, P. J. (2007) · Cancer · doi:10.1002/cncr.23034 · Cited by 73
Hasani, A., Alvarez, J. M., Wyatt, J. M., Bydder, S. A., Millward, M., Byrne, M., Musk, A. W., & Nowak, A. K. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ae25bf · Cited by 73
Wolanski, K., Whitaker, D., SHILKIN, K. B., & Henderson, D. W. (1998) · Cancer · Cited by 72
GENE THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA
Sterman, D. H., Kaiser, L. R., & Albelda, S. Μ. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70008-3 · Cited by 72
Richards, W. G., Godleski, J. J., Yeap, B. Y., et al. (2010) · Cancer · doi:10.1002/cncr.24886 · Cited by 72
Samson, M. K., Wasser, L. P., Borden, E. C., Wanebo, H. J., Creech, R. H., Phillips, M., & Baker, L. H. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.86 · Cited by 72
Cellular and molecular parameters of mesothelioma
Ramos‐Nino, M. E., Testa, J. R., Altomare, D. A., Pass, H. I., Carbone, M., Bocchetta, M., & Mossman, B. T. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20828 · Cited by 71
Kushitani, K., Takeshima, Y., Amatya, V. J., Furonaka, O., Sakatani, A., & Inai, K. (2008) · Pathology International · doi:10.1111/j.1440-1827.2007.02193.x · Cited by 71
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats
Sandhu, H., Dehnen, W., Roller, M., Abel, J., & Unfried, K. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.1023 · Cited by 71
Soulié, P., Ruffiè, P., Trandafir, L., Monnet, I., Tardivon, A. A., Terrier, P., Cvitkovic, E., Chevalier, T. L., & Armand, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.878 · Cited by 71
Current Trends in Radiologic Management of Malignant Pleural Mesothelioma
Gill, R. R., Gerbaudo, V. H., Sugarbaker, D. J., et al. (2009) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2009.06.011 · Cited by 70
Taylor, P., Castagneto, B., Dark, G. G., Marangolo, M., Scagliotti, G. V., van Klaveren, R. J., Labianca, R., Serke, M. H., Schuette, W., van Meerbeeck, J. P., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c73ec · Cited by 69
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
Castagneto, B., Zai, S., Dongiovanni, D., Muzio, A., Bretti, S., Numico, G., & Botta, M. (2005) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000144852.75613.56 · Cited by 69
Lymphocytic infiltration of pleural mesothelioma and its significance for survival.
Ra, L., & Webster, I. (1982) · PubMed · Cited by 67
Jagirdar, J. S., Lee, T. C., Reibman, J., Gold, L. I., Aston, C., Begin, R. O., & Rom, W. N. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.97105s51197 · Cited by 66
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
Gordon, G. J., Mani, M., Maulik, G., Mukhopadhyay, L., Yeap, B. Y., Kindler, H. L., Salgia, R., Sugarbaker, D. J., & Bueno, R. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0500-1 · Cited by 66
Self-citationCurrent Status of Screening for Malignant Pleural Mesothelioma
Pass, H. I., & Carbone, M. (2009) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2009.06.007 · Cited by 66
Three decades of experience in the surgical multi-modality management of pleural mesothelioma
Luckraz, H., Rahman, M., Patel, N. N., Szafranek, A., Gibbs, A. R., & Butchart, E. G. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.07.032 · Cited by 66
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
König, J.-E., Tolnay, E., Wiethege, T., & Müller, K.-M. (1999) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050388 · Cited by 65
Second-line treatment for malignant pleural mesothelioma
Ceresoli, G. L., Zucali, P. A., Gianoncelli, L., Lorenzi, E., & Santoro, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.09.003 · Cited by 65
(1994) · PubMed · Cited by 65
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
Oxnard, G. R., Armato, S. G., & Kindler, H. L. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.12.013 · Cited by 64
Self-citationRanpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma
Pavlakis, N., & Vogelzang, N. J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.4.391 · Cited by 64
Patterns of failure following surgical resection for malignant pleural mesothelioma
Janne, P. A., & Baldini, E. H. (2004) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2004.06.006 · Cited by 62
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis
Luo, L., Shi, H., Liang, Q.-L., Jiang, J., Qin, S., & Deng, J. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.05.017 · Cited by 62
Cytokine Gene Therapy or Infusion as Treatment for Solid Human Cancer
Robinson, B. W. S., Mukherjee, S., Davidson, A., Morey, S., Musk, A. W., Ramshaw, I. A., Smith, D. W., Lake, R., Haenel, T., Garlepp, M. J., et al. (1998) · Journal of Immunotherapy · doi:10.1097/00002371-199805000-00007 · Cited by 62
Kalmadi, S. R., Rankin, C. J., Kraut, M., Jacobs, A. D., Petrylak, D. P., Adelstein, D. J., Keohan, M. L., Taub, R. N., & Borden, E. C. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.09.018 · Cited by 61
The Nf2 tumor suppressor regulates cell–cell adhesion during tissue fusion
McLaughlin, M. E., Crane, G. M., Slocum, K. L., Crowley, D. G., Michaud, N. A., Huang, J. J., Magendantz, M., & Jacks, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700044104 · Cited by 61
Mattson, K. V., Giaccone, G., Kirkpatrick, A., Evrard, D., Tammilehto, L., van Breukelen, F. J. M., Planteydt, H. T., & van Zandwijk, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.824 · Cited by 61
Malignant mesothelioma following treatment for Hodgkin's disease.
Weissmann, L. B., Corson, J. M., Neugut, A. I., & Antman, K. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2098 · Cited by 61
Assessment of tumor response in malignant pleural mesothelioma
Ceresoli, G. L., Chiti, A., Zucali, P. A., Cappuzzo, F., Vincenzo, F. D., Cavina, R., Rodari, M., Poretti, D., Lutman, R. F., & Santoro, A. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.012 · Cited by 60
Computerized segmentation and measurement of malignant pleural mesothelioma
Sensakovic, W. F., Armato, S. G., Straus, C. M., Roberts, R. Y., Caligiuri, P., Starkey, A., & Kindler, H. L. (2010) · Medical Physics · doi:10.1118/1.3525836 · Cited by 60
Self-citationPilling, J. E., Stewart, D. J., Martin-Ucar, A. E., et al. (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2003.12.001 · Cited by 59
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study
Upham, J. W., Musk, A. W., van Hazel, G., Byrne, M., & Robinson, B. W. S. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb04727.x · Cited by 59
Wilcox, B. E., Subramaniam, R. M., Peller, P. J., Aughenbaugh, G. L., Nichols, F. C., Aubry, M. C., & Jett, J. R. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.033 · Cited by 58
False positive 18F-FDG-PET/CT in a patient after talc pleurodesis
Ahmadzadehfar, H., PALMEDO, H., Strunk, H. M., Biersack, H., Habibi, E., & Ezziddin, S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.015 · Cited by 58
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma
Sandberg, A. A., & Bridge, J. A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00432-0 · Cited by 58
Bielefeldt‐Ohmann, H., Fitzpatrick, D. R., Marzo, A. L., Jarnicki, A., Himbeck, R. P., Davis, M. R., Manning, L. S., & Robinson, B. W. S. (1994) · Cancer Immunology Immunotherapy · doi:10.1007/bf01534421 · Cited by 57
Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene
Esandi, M. C., van Someren, G., Vincent, A. J. P. E., van Bekkum, D., Valerio, D., Bout, A., & Noteboom, J. L. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300385 · Cited by 56
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
Sørensen, J. B., Frank, H., & Palshof, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604421 · Cited by 56
Cj, L., Mercke, C., Albrechtsson, U., et al. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09122565 · Cited by 54
Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine
Boutin, C., Loddenkemper, R., & Astoul, P. J. (1993) · Tubercle and Lung Disease · doi:10.1016/0962-8479(93)90048-3 · Cited by 54
Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002
Larson, T. C., III, Melnikova, N., Davis, S. I., & Jamison, P. M. (2007) · International Journal of Occupational and Environmental Health · doi:10.1179/oeh.2007.13.4.398 · Cited by 53
Allen, A. M., Den, R. B., Wong, J. S., Zurakowski, D., Soto, R., Janne, P. A., Zellos, L. S., Bueno, R., Sugarbaker, D. J., & Baldini, E. H. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.02.047 · Cited by 53
Sørensen, J. B., Sundstrøm, S. H., Perell, K. A., & Thielsen, A.-K. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31802f3813 · Cited by 52
The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
Chirieac, L. R., Pinkus, G. S., Pinkus, J. L., Godleski, J. J., Sugarbaker, D. J., & Corson, J. M. (2011) · Europe PMC (PubMed Central) · Cited by 52
Somatic genetic alterations in human malignant mesothelioma (review).
Lee, W. C., & Testa, J. R. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.1.181 · Cited by 52
Chemotherapy for Malignant Pleural Mesothelioma
Janne, P. A. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.023 · Cited by 51
Novel marker D2‐40, combined with calretinin, CEA, and TTF‐1
Mimura, T., Ito, A., Sakuma, T., et al. (2007) · Cancer · doi:10.1002/cncr.22477 · Cited by 50
Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma
Boulangé-Lecomte, C., Andujar, P., Renier, A., Kheuang, L., Abramowski, V., Mellotte, L., Fleury‐Feith, J., Zucman‐Rossi, J., Giovanni, M. D., & Jaurand, M. (2005) · Cell Cycle · doi:10.4161/cc.4.12.2300 · Cited by 50
Destro, A., Ceresoli, G. L., Baryshnikova, E., Garassino, I. M. G., Zucali, P. A., Vincenzo, F. D., Bianchi, P. P., Morenghi, E., Testori, A., Alloisio, M., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.035 · Cited by 49
Noppen, M. M. P., Grève, J. D., Mignolet, M., & Vincken, W. (1997) · Acta Clinica Belgica · doi:10.1080/17843286.1997.11718587 · Cited by 47
Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naïve Malignant Pleural Mesothelioma
Janne, P. A., Simon, G. R., Langer, C. J., Taub, R. N., Dowlati, A., Fidias, P., Monberg, M., Obasaju, C. K., & Kindler, H. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7611 · Cited by 47
Self-citationExternal beam radiation therapy for the treatment of pleural mesothelioma
Baldini, E. H. (2004) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/s1547-4127(04)00108-2 · Cited by 46
Photodynamic Therapy as an Innovative Treatment for Malignant Pleural Mesothelioma
Friedberg, J. S. (2009) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2009.07.001 · Cited by 46
Epirubicin in the Treatment of Malignant Mesothelioma: A Phase II Cooperative Study
Magri, M. D., Veronesi, A., Foladore, S., Giovanni, D. D., Serra, C., Crismancich, F., Tuveri, G., Nicotra, M., Tommasi, M., Morassut, S., et al. (1991) · Tumori Journal · doi:10.1177/030089169107700112 · Cited by 46
Integration of Multimodality Approaches in the Management of Malignant Pleural Mesothelioma
Martino, D., & Pass, H. I. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.008 · Cited by 43
Maeda, J., Ueki, N., Ohkawa, T., Iwahashi, N., Nakano, T., HADA, T., & Higashino, K. (1994) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06144.x · Cited by 43
Phase II Study of Vinflunine in Malignant Pleural Mesothelioma
Talbot, D. C., Margery, J., Dabouis, G., Dark, G. G., Taylor, H., Boussemart, H., Cadic, V., Pinel, M., Rivière, A., Ollivier, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5641 · Cited by 42
Schmucker, B., Tang, Y., & Kressel, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1561 · Cited by 42
Sonnemann, J., Hartwig, M., Plath, A., Kumar, K. S., Müller, C., & Beck, J. F. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.009 · Cited by 41
Andreopoulou, E., Ross, P. J., O'Brien, M. E. R., Ford, H. E. R., Priest, K., Eisen, T., Norton, A., Ashley, S., & Smith, I. E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh356 · Cited by 41
Dirix, L. Y., van Meerbeeck, J. P., Schrijvers, D. M., Corthouts, B., Prové, A., Marck, E. V., Vermeire, P. A., & van Oosterom, A. T. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058941 · Cited by 40
What's the place of immunotherapy in malignant mesothelioma treatments?
Grégoire, M. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.11361 · Cited by 39
Potential for Interferon-α-Based Therapy in Mesothelioma: Assessment in a Murine Model
Bielefeldt‐Ohmann, H., FITZPATRICK, D. R., Marzo, A. L., Jarnicki, A., Musk, A. W., & Robinson, B. W. S. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.213 · Cited by 39
Cantwell, B. M. J., Earnshaw, M., & Harris, A. L. (1986) · PubMed · Cited by 39
in vitro effects of recombinant human interferon gamma on human mesothelioma cell lines
Zeng, L., Buard, A., Saint-Etienne, L., Jaurand, M., Bignon, J., Monnet, I., Brochard, P., Boutin, C., & Fleury‐Feith, J. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550331 · Cited by 36
Elshami, A. A., Kucharczuk, J. C., Sterman, D. H., Smythe, W. R., Hwang, H. C., Amin, K. M., Litzky, L. A., Albelda, S. Μ., & Kaiser, L. R. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00008 · Cited by 36
Prevalence and Pattern of Lymph Node Metastasis in Malignant Pleural Mesothelioma
Rahman, A. R. M. A., Gaafar, R. M., Baki, H. A. E., Hosieny, H. M. E., Aboulkasem, F., Farahat, E. G., Nouh, M. A., & Mansour, K. A. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.04.012 · Cited by 35
CT, RECIST, and malignant pleural mesothelioma
Nowak, A. K. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.030 · Cited by 35
Xie, Y., Hwang, C., Overwijk, W. W., Zeng, Z., Eng, M. H., Mulé, J. J., Imperiale, M. J., Restifo, N. P., & Sanda, M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.169 · Cited by 35
An Overview of Chemotherapy for Mesothelioma
Krug, L. M. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.09.010 · Cited by 33
Ali, Y., Lin, Y., Gharibo, M. M., Gounder, M. K., Stein, M. N., Lagattuta, T. F., Egorin, M. J., Rubin, E. H., & Poplin, E. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0883 · Cited by 33
Irinotecan for malignant mesothelioma
Kindler, H. L., Herndon, J. E., Zhang, C., & Green, M. R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.12.002 · Cited by 32
Self-citationMilne, J. E. H. (1976) · Occupational and Environmental Medicine · doi:10.1136/oem.33.2.115 · Cited by 32
The Role of Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
Waite, K., & Gilligan, D. (2007) · Clinical Oncology · doi:10.1016/j.clon.2006.12.006 · Cited by 31
Antiangiogenic Therapies for Mesothelioma
Dowell, J. E., & Kindler, H. L. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.09.008 · Cited by 29
Self-citationTreatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II cooperative study
Magri, M. D., Foladore, S., Veronesi, A., Serra, C., Nicotra, M., Tommasi, M., Grandi, G., Monfardini, S., & Bianchi, C. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058159 · Cited by 29
Rienzo, A. D., Dong, L., Yeap, B. Y., Jensen, R. V., Richards, W. G., Gordon, G. J., Sugarbaker, D. J., & Bueno, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0806 · Cited by 28
Pleural-based mesothelioma in immune competent rats: A model to study adenoviral gene transfer
Kucharczuk, J. C., Elshami, A. A., Zhang, H. B., et al. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00507-h · Cited by 27
P450 Cytochromes and Hormonal Regulation: An Overview
Jefcoate, C. R. E. (1996) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(08)60338-0 · Cited by 26
Tochner, Z. A., Pass, H. I., Smith, P. D., DeLaney, T. F., Sprague, M., DeLuca, A. M., Harrington, F. S., Thomas, G. F., Terrill, R. E., Bacher, J. D., et al. (1994) · Lasers in Surgery and Medicine · doi:10.1002/1096-9101(1994)14:2<118::aid-lsm1900140204>3.0.co;2-5 · Cited by 24
Immunotherapy with BCG vaccine in 30 cases of mesothelioma.
Webster, I., Cochrane, J. W. C., & Burkhardt, K. R. (1982) · PubMed · Cited by 24
Malignant pleural mesothelioma
Ceresoli, G. L., Betta, G. P., Castagneto, B., Facciolo, F., Arcangeli, G., Zucali, P. A., Libener, R., Giovanni, D. D., Melis, E., & Mirri, M. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj912 · Cited by 23
van Meerbeeck, J. P., & Hillerdal, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200806-955ed · Cited by 23
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
Nakas, A., Black, E., Entwisle, J. J., Muller, S., & Waller, D. A. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.12.039 · Cited by 23
Mohiuddin, I. T., Cao, X. X., Özvaran, M. K., Zumstein, L., Chada, S., & Smythe, W. R. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02573071 · Cited by 22
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Kotsakis, A. P., & Georgoulias, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498581 · Cited by 21
Familial heterogeneity of colon cancer risk
Lynch, H. T., Kimberling, W. J., Biscone, K. A., Lynch, J. F., Wagner, C. A., Brennan, K., Mailliard, J. A., Johnson, P. S., Soori, J. S., & McKenna, P. (1986) · Cancer · doi:10.1002/1097-0142(19860515)57:10<1905::aid-cncr2820571003>3.0.co;2-j · Cited by 20
Use of photodynamic therapy for the management of pleural malignancies
Pass, H. I., & Donington, J. S. (1995) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980110506 · Cited by 19
Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients.
Ak, G., Metintaş, M., Yıldırım, H., Metintaş, S., Dündar, E., Erginel, S., & Alataş, F. (2009) · PubMed · Cited by 12
Simian virus 40 oncogenesis in hamsters.
Carbone, M., Stach, R. M., Resta, I. D., et al. (1998) · PubMed · Cited by 12
Extrapleural pneumonectomy for malignant mesothelioma.
Dj, S., Richards, W. G., & Jp, G. (1997) · PubMed · Cited by 11
Translational therapies for malignant pleural mesothelioma
Belli, C., Anand, S. K., Tassi, G., Fennell, D. A., & Mutti, L. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.17 · Cited by 9
ACR Appropriateness Criteria® Chronic Dyspnea
Dyer, D. S., Mohammed, T.-L. H., Kirsch, J., et al. (2013) · Journal of Thoracic Imaging · doi:10.1097/rti.0b013e31829a2dc3 · Cited by 8
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
(1995) · PubMed
(2003) · PubMed
Cited by
RECIST revisited: A review of validation studies on tumour assessment
Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.026 · Cited by 422
Kao, S. C. H., Pavlakis, N., Harvie, R., Vardy, J. L., Boyer, M. J., van Zandwijk, N., & Clarke, S. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2245 · Cited by 316
Measures of Response: RECIST, WHO, and New Alternatives
Jaffe, C. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5599 · Cited by 302
Molecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
Metadata
- Authors
- Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-04-20
- Volume
- 27
- Issue
- 12
- Pages
- 2081-2090
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095824051
- Cited by
- 481
- References
- 344
- FWCI
- 31.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.